WuXi Biologics has unveiled WuXia293Stable, a cutting-edge platform tailored for the development and manufacturing of challenging-to-express molecules that are stably expressed in HEK293 cells. This innovative platform boasts high titers, robust stability, and superior quality, enhancing the feasibility and scalability of intricate biologics. By leveraging its proprietary HEK293 cell line, WuXi Biologics has created a solution that addresses the limitations of traditional CHO cells, offering a highly efficient CMC (Chemistry, Manufacturing, and Control) solution for biologics with complex structures and functions.
The WuXia293Stable platform has demonstrated exceptional productivity, quality, and stability, achieving a fed-batch titer of up to 5.0 g/L for monoclonal antibodies while enhancing purity. Notably, this platform maintains stable expression and consistent quality over prolonged cell passages, facilitating scalable manufacturing at both clinical and commercial levels. WuXi Biologics’ comprehensive suite of services for the WuXia293Stable platform includes cell bank testing and viral clearance validation, providing a holistic CMC solution for clients.
Dr. Chris Chen, the CEO of WuXi Biologics, emphasized the platform’s role in advancing the development of advanced therapeutics and reaffirmed the company’s commitment to innovation and meeting the evolving needs of the biopharmaceutical industry. WuXia293Stable is a testament to WuXi Biologics’ dedication to enabling the accelerated delivery of innovative biologics to patients globally. The platform is part of the WuXia™ cell line development platform family, which includes WuXiaADCCPlus™ for afucosylated antibodies and WuXia RidGS™ for non-antibiotic cell line development.
The WuXia™ platform family, with its high-yield mammalian cell lines, has been widely accepted by regulatory agencies worldwide, having generated over 1000 cell lines expressing various biologics for clinical and commercial manufacturing. WuXi Biologics continues to expand its platform offerings to cater to the diverse requirements of global customers, ensuring that every biologic can be efficiently developed and manufactured. The launch of WuXia293Stable marks a significant milestone in the biologics development landscape, providing researchers and biopharmaceutical companies with a powerful tool to advance the next generation of therapeutic molecules.
Key Takeaways:
– WuXi Biologics’ WuXia293Stable platform offers a highly efficient CMC solution for developing challenging-to-express molecules.
– The platform achieves a fed-batch titer of up to 5.0 g/L for monoclonal antibodies while enhancing purity, scalability, and consistency.
– WuXia293Stable is part of the WuXia™ platform family, which includes other specialized platforms like WuXiaADCCPlus™ and WuXia RidGS™ to meet diverse customer needs.
– WuXi Biologics continues to lead in technological innovation, enabling the accelerated delivery of innovative biologics to patients worldwide.
Tags: monoclonal antibodies, regulatory
Read more on finance.yahoo.com
Click link–> to learn about: What’s the Optimum Phytase Expression Temperature in Pichia pastoris?